Karolinska Development AB (publ) (KDEV.ST)
SEK 1.07
(3.5%)
SEK 1.07
(3.5%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 5.38 Million SEK | 103.71% |
| 2022 | -145.03 Million SEK | -140.99% |
| 2021 | 353.84 Million SEK | 191.79% |
| 2020 | -385.47 Million SEK | -158.61% |
| 2019 | 657.7 Million SEK | 2055.72% |
| 2018 | 30.51 Million SEK | -83.01% |
| 2017 | 179.59 Million SEK | 182.83% |
| 2016 | -216.83 Million SEK | 79.44% |
| 2015 | -1.05 Billion SEK | -180.64% |
| 2014 | -375.81 Million SEK | -290.61% |
| 2013 | 197.16 Million SEK | 192.63% |
| 2012 | -212.85 Million SEK | 44.81% |
| 2011 | -385.67 Million SEK | -15.27% |
| 2010 | -334.58 Million SEK | -12568.84% |
| 2009 | -2.64 Million SEK | 54.2% |
| 2008 | -5.76 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 208 Thousand SEK | 111.12% |
| 2024 Q2 | -15.99 Million SEK | -7788.46% |
| 2023 FY | 5.38 Million SEK | 103.71% |
| 2023 Q4 | -1.87 Million SEK | -115.58% |
| 2023 Q3 | 12 Million SEK | -48.39% |
| 2023 Q1 | -71.21 Million SEK | -172.47% |
| 2023 Q2 | 23.26 Million SEK | 132.67% |
| 2022 Q4 | 98.27 Million SEK | 313.16% |
| 2022 Q2 | -23.81 Million SEK | 20.96% |
| 2022 Q1 | -30.13 Million SEK | -54.58% |
| 2022 FY | -145.03 Million SEK | -140.99% |
| 2022 Q3 | -46.1 Million SEK | -93.57% |
| 2021 Q3 | -1.19 Million SEK | -100.55% |
| 2021 Q2 | 216.39 Million SEK | 969.48% |
| 2021 Q4 | -19.49 Million SEK | -1531.3% |
| 2021 FY | 353.84 Million SEK | 191.79% |
| 2021 Q1 | -24.88 Million SEK | -128.97% |
| 2020 Q1 | -126.14 Million SEK | -138.37% |
| 2020 FY | -385.47 Million SEK | -158.61% |
| 2020 Q3 | -169.36 Million SEK | -8168.7% |
| 2020 Q4 | 85.91 Million SEK | 150.73% |
| 2020 Q2 | 2.09 Million SEK | 101.66% |
| 2019 Q2 | 7.47 Million SEK | 140.11% |
| 2019 Q4 | 328.78 Million SEK | 2343.67% |
| 2019 FY | 657.7 Million SEK | 2055.72% |
| 2019 Q3 | -14.65 Million SEK | -296.15% |
| 2019 Q1 | -18.62 Million SEK | -225.4% |
| 2018 Q3 | 4.07 Million SEK | -86.99% |
| 2018 Q1 | -19.72 Million SEK | -161.74% |
| 2018 FY | 30.51 Million SEK | -83.01% |
| 2018 Q4 | 14.85 Million SEK | 264.69% |
| 2018 Q2 | 31.3 Million SEK | 258.72% |
| 2017 Q1 | -25.18 Million SEK | -9.46% |
| 2017 Q4 | 31.95 Million SEK | -83.54% |
| 2017 Q2 | -21.25 Million SEK | 15.64% |
| 2017 FY | 179.59 Million SEK | 182.83% |
| 2017 Q3 | 194.08 Million SEK | 1013.33% |
| 2016 Q1 | -100.09 Million SEK | 17.68% |
| 2016 FY | -216.83 Million SEK | 79.44% |
| 2016 Q3 | -17.88 Million SEK | 76.42% |
| 2016 Q4 | -23.01 Million SEK | -28.7% |
| 2016 Q2 | -75.84 Million SEK | 24.23% |
| 2015 Q3 | -27.52 Million SEK | 95.8% |
| 2015 FY | -1.05 Billion SEK | -180.64% |
| 2015 Q1 | -275.07 Million SEK | -591.13% |
| 2015 Q2 | -654.63 Million SEK | -137.98% |
| 2015 Q4 | -121.59 Million SEK | -341.84% |
| 2014 Q2 | -189.51 Million SEK | -931.67% |
| 2014 FY | -375.81 Million SEK | -290.61% |
| 2014 Q4 | -39.8 Million SEK | 68.94% |
| 2014 Q3 | -128.12 Million SEK | 32.39% |
| 2014 Q1 | -18.37 Million SEK | 83.53% |
| 2013 Q4 | -111.51 Million SEK | -24.37% |
| 2013 Q3 | -89.66 Million SEK | -2561.97% |
| 2013 Q2 | 3.64 Million SEK | -99.08% |
| 2013 FY | 197.16 Million SEK | 192.63% |
| 2013 Q1 | 394.7 Million SEK | 407.07% |
| 2012 Q2 | -88.91 Million SEK | 0.23% |
| 2012 Q1 | -89.11 Million SEK | 34.68% |
| 2012 Q4 | 77.84 Million SEK | 164.93% |
| 2012 Q3 | -119.87 Million SEK | -34.83% |
| 2012 FY | -212.85 Million SEK | 44.81% |
| 2011 Q1 | -37.54 Million SEK | 0.0% |
| 2011 Q4 | -136.44 Million SEK | -6.53% |
| 2011 FY | -385.67 Million SEK | -15.27% |
| 2011 Q2 | -86.61 Million SEK | -130.69% |
| 2011 Q3 | -128.08 Million SEK | -47.88% |
| 2010 FY | -334.58 Million SEK | -12568.84% |
| 2010 Q3 | - SEK | 0.0% |
| 2009 FY | -2.64 Million SEK | 54.2% |
| 2008 FY | -5.76 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -248.58 Million SEK | 102.167% |
| Ziccum AB (publ) | -21.41 Million SEK | 125.154% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | 130.094% |
| BioArctic AB (publ) | 229.24 Million SEK | 97.651% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | 1329.68% |
| Mendus AB (publ) | -101.61 Million SEK | 105.3% |
| Genovis AB (publ.) | 61.5 Million SEK | 91.242% |
| Intervacc AB (publ) | -102.85 Million SEK | 105.237% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | 132.597% |
| Active Biotech AB (publ) | -45.8 Million SEK | 111.76% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 55.74% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | 109.479% |
| Aptahem AB (publ) | -11.11 Million SEK | 148.466% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | 101.732% |
| Kancera AB (publ) | -64.88 Million SEK | 108.3% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | 104.376% |
| Fluicell AB (publ) | -26.55 Million SEK | 120.283% |
| Saniona AB (publ) | -95.81 Million SEK | 105.622% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | 144.41% |
| Biovica International AB (publ) | -124.82 Million SEK | 104.315% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 112.756% |
| AcouSort AB (publ) | -17.08 Million SEK | 131.517% |
| Xintela AB (publ) | -54.08 Million SEK | 109.959% |
| Abliva AB (publ) | -95.5 Million SEK | 105.639% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | 101.648% |
| OncoZenge AB (publ) | -15.9 Million SEK | 133.87% |
| Amniotics AB (publ) | -30.87 Million SEK | 117.447% |
| 2cureX AB (publ) | -32.51 Million SEK | 116.563% |
| CombiGene AB (publ) | -35.66 Million SEK | 115.101% |
| Asarina Pharma AB (publ) | -12.82 Million SEK | 141.986% |
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 101.155% |
| Camurus AB (publ) | 431.44 Million SEK | 98.752% |
| Corline Biomedical AB | -1.8 Million SEK | 397.734% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | 103.029% |
| Isofol Medical AB (publ) | -37.07 Million SEK | 114.529% |
| I-Tech AB | 20.2 Million SEK | 73.341% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 100.648% |
| Cyxone AB (publ) | -22.98 Million SEK | 123.429% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | 105.893% |
| Biosergen AB | -27.03 Million SEK | 119.921% |
| Cantargia AB (publ) | -280.02 Million SEK | 101.923% |
| NextCell Pharma AB | -41.95 Million SEK | 112.836% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | 102.998% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | 132.846% |
| Nanologica AB (publ) | -75.15 Million SEK | 107.166% |
| SynAct Pharma AB | -215.81 Million SEK | 102.496% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | 112.226% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | 122.69% |
| LIDDS AB (publ) | -40.2 Million SEK | 113.396% |
| Lipum AB (publ) | -37.17 Million SEK | 114.487% |
| BioInvent International AB (publ) | -330.3 Million SEK | 101.631% |
| Alzinova AB (publ) | -16.48 Million SEK | 132.682% |
| Oncopeptides AB (publ) | -249.11 Million SEK | 102.162% |
| Pila Pharma AB (publ) | -9.93 Million SEK | 154.24% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | 104.753% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | 125.537% |
| Simris Alg AB (publ) | -37.3 Million SEK | 114.438% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | 103.547% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 101.388% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | 104.928% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | 146.121% |